目的:为减少放、化疗及中药的不良反应,提高肿瘤患者的生活质量。方法:经外周静脉穿刺中心静脉置管(Peripherally inserted central catheter PICC)的微量注射泵,用于持续输注化疗药物5—氟尿嘧啶,羟基喜树碱、诺维本、阿霉素等治疗食...目的:为减少放、化疗及中药的不良反应,提高肿瘤患者的生活质量。方法:经外周静脉穿刺中心静脉置管(Peripherally inserted central catheter PICC)的微量注射泵,用于持续输注化疗药物5—氟尿嘧啶,羟基喜树碱、诺维本、阿霉素等治疗食管癌、胃癌、结肠癌、乳腺癌等。结果:通过24例次中晚期肿瘤患者应用PICC配合微量注射泵持续输注化疗的临床观察,总结PICC配合微量输液泵在化疗中的应用和护理体会。结论:PICC配合使用微量输注泵,操作简单,便于携带,使用方便,避免了化疗药物对血管的刺激,减轻化疗药物的不良反应,提高了化疗疗效,改善了患者的生活质量。展开更多
Objective： We assessed the safety and efficacy of two regimens for patients with gastrointestinal cancers： continuous-infusion （CI） schedules of 5-Fluorouracil （5-Fu） plus a platinum （cisplatin or oxaliplatin）...Objective： We assessed the safety and efficacy of two regimens for patients with gastrointestinal cancers： continuous-infusion （CI） schedules of 5-Fluorouracil （5-Fu） plus a platinum （cisplatin or oxaliplatin） with/or without paclitaxel （regimen A） versus Xeloda plus a platinum （cisplatin or oxaliplatin） with/or without paclitaxel for oral use （regimen B） in patients with gastrointestinal cancers. Methods： Between May 2003 and May 2005, 84 patients diagnosed in Jiangsu Cancer Hospital ＆ Research Institute with locally advanced esophageal, gastnc or colorectal cancer were registered. Regimen A and B consisted of either 5-Fu 0.375 CI days 1-14, every 28 days （n = 44）, or Xeloda 1000 mg twice daily, days 1-14, every 28 days （n = 40）. For both regimen A and B, IV cisplatin 25 mg/m^2 was administered on day 1, 2 and 3 （or Oxaliplatin 75mg/m^2 on day 1, 8 and 15） with or without paclitaxel 60-75 mg/m^2 on day1, 8 and 15. Results： Patients receiving regimen B experienced significantly less stomatitis （P 〈 0.05） and diarrhea （P 〈 0.05）, than those receiving regimen A. Prevalence of nausea/vomiting, alopecia, neutropenia, and hand-foot syndrome without significant difference between two regimens. No treatment related death occurred during study period. Regimen B demonstrates a similar, favorable safety profile in this study. Response rates and rates of clinical benefit for regimen A and B were 40.9%, 40.0% and 43.2%, 65.0% respectively. Conclusion： Based on its improved safety profile and improved rate of clinical benefit, Xeloda has the potential to replace CI 5-FU as an alternative treatment for patients with gastrointestinal cancers.展开更多
文摘目的:为减少放、化疗及中药的不良反应,提高肿瘤患者的生活质量。方法:经外周静脉穿刺中心静脉置管(Peripherally inserted central catheter PICC)的微量注射泵,用于持续输注化疗药物5—氟尿嘧啶,羟基喜树碱、诺维本、阿霉素等治疗食管癌、胃癌、结肠癌、乳腺癌等。结果:通过24例次中晚期肿瘤患者应用PICC配合微量注射泵持续输注化疗的临床观察,总结PICC配合微量输液泵在化疗中的应用和护理体会。结论:PICC配合使用微量输注泵,操作简单,便于携带,使用方便,避免了化疗药物对血管的刺激,减轻化疗药物的不良反应,提高了化疗疗效,改善了患者的生活质量。
基金Supported by grants from the Jiangsu Provincial Personnel Department "the Great of Six Talented Man Peak" Project and the Jiangsu Cancer Hospital Emphasis Project (No. ZK200602).
文摘Objective： We assessed the safety and efficacy of two regimens for patients with gastrointestinal cancers： continuous-infusion （CI） schedules of 5-Fluorouracil （5-Fu） plus a platinum （cisplatin or oxaliplatin） with/or without paclitaxel （regimen A） versus Xeloda plus a platinum （cisplatin or oxaliplatin） with/or without paclitaxel for oral use （regimen B） in patients with gastrointestinal cancers. Methods： Between May 2003 and May 2005, 84 patients diagnosed in Jiangsu Cancer Hospital ＆ Research Institute with locally advanced esophageal, gastnc or colorectal cancer were registered. Regimen A and B consisted of either 5-Fu 0.375 CI days 1-14, every 28 days （n = 44）, or Xeloda 1000 mg twice daily, days 1-14, every 28 days （n = 40）. For both regimen A and B, IV cisplatin 25 mg/m^2 was administered on day 1, 2 and 3 （or Oxaliplatin 75mg/m^2 on day 1, 8 and 15） with or without paclitaxel 60-75 mg/m^2 on day1, 8 and 15. Results： Patients receiving regimen B experienced significantly less stomatitis （P 〈 0.05） and diarrhea （P 〈 0.05）, than those receiving regimen A. Prevalence of nausea/vomiting, alopecia, neutropenia, and hand-foot syndrome without significant difference between two regimens. No treatment related death occurred during study period. Regimen B demonstrates a similar, favorable safety profile in this study. Response rates and rates of clinical benefit for regimen A and B were 40.9%, 40.0% and 43.2%, 65.0% respectively. Conclusion： Based on its improved safety profile and improved rate of clinical benefit, Xeloda has the potential to replace CI 5-FU as an alternative treatment for patients with gastrointestinal cancers.
